Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
- Study ID
- NCT01019668
- Status
- Completed
Conditions
- Central Serous Chorioretinopathy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Verteporfin PDT, half-dose — DRUGhalf the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
- verteporfin PDT, half-fluence — DRUGhalf the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Study Details
The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved central serous chorioretinopathy (CSCR).
Key Dates
- Start date
- Nov 30, 2008
- Status verified
- Jul 2011
- Primary completion
- Dec 31, 2009
- Completion
- Jun 30, 2011
Study Design
- Enrollment
- 24 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: verteporfin PDT, half-doseuse different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
- Active Comparator: verteporfin PDT, half-fluenceuse different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
Primary Outcome Measure
Effectiveness of both modification for the treatment of chronic CSCR Fluorescent leakage as regards to BCVA OCT changes [ Time Frame: within 6 months ]
Related Studies
- OCT in Rare Chorioretinal DiseasesRecruiting · Oregon Health and Science University · Portland, Oregon